ALPANA Ventures

Resistell raised CHF 3.5m in a Series A funding round

Our new portfolio company, RESITELL, raised CHF 3.5m in a Series A funding round.

RESISTELL is a Swiss Medtech startup determining, in a very short timeframe, the right antibiotic depending on the resistance of pathogens. The fundraising round will support the achievement of the CE-mark approval for its first device testing blood stream infections.

Read the press release.